Tormere Analytics
OverviewStock ResearchChartsPortfolio LabOptions LabCalculatorsWatchlist
Data Explorer
Articles
Pricing
Privacy PolicyTerms of Service

FDMT

$13.67-1.23%website ↗⬇ financials (.py)

4D Molecular Therapeutics, Inc.

Market Cap
$715M
Live price × shares (2026-09-17)
Sector
Health Care
Industry
Biotechnology
Beta (raw)
2.71
60mo monthly vs SPY
P/E (TTM)
N/M
Price / TTM net income
P/S (TTM)
7.8
Price / TTM revenue
P/B
1.8
Price / stockholders equity
EV/EBITDA
—
TTM
Price Chart
Loading…

Signals

Insider Velocity
3896.3x
selling
Congress
—
recent trades
Short Volume
70%
W/W +0.5pp

Market & Alt Data

News
15
recent articles
Activist
—
none active
Analyst Consensus
Strong Buy
18 analysts
Velocity Score
3896.32x
Sell Rate (90d)
2495.99/mo
Sell Baseline
1.59/mo
Unique Sellers (90d)
2
Sort by
Type
Trade DateFiledOwnerRoleTypeSharesPriceValueOwned After
2026-09-162026-09-22Bizily ScottChief Legal OfficerSale1,635$13.65$22K8,617View
2026-09-142026-09-16Kirn DavidDirector & See RemarksSale58.3K$13.90$811K767.5KView
2026-09-012026-09-03Bizily ScottChief Legal OfficerSale584$14.00$8K8,617View
2026-08-192026-08-21Kirn DavidDirector & See RemarksSale69.1K$15.75$1.09M825.8KView
2026-08-172026-08-17Bizily ScottChief Legal OfficerSale1,635$12.20$20K8,617View
1–5 of 13
1 / 3

Reporting Insiders

  • Scott Bizily
    Chief Legal Officer
    5 transactions · last 2026-09-16
  • David Kirn
    Director & See Remarks
    7 transactions · last 2026-09-14
  • Scott Bizily
    Chief Legal Officer
    1 transaction · last 2026-06-23
  • David Kirn
    Director & See Remarks
    1 transaction · last 2026-06-22
  • Ashoo Gupta
    VP, Finance and Controller
    2 transactions · last 2026-03-20

Recent News

Insiders At 4D Molecular Therapeutics Sold US$757k In Stock, Alluding To Potential Weakness
Moomoo · 2026-09-30
4D Molecular Therapeutics Insiders Sold US$757k Of Shares Suggesting Hesitancy
Simply Wall Street · 2026-09-30
This is the top biotech stock pick from B Riley Securities
Yahoo · 2026-09-29
4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway
SeekingAlpha · 2026-09-29
FDMT Maintains by B of A Securities -- Price Target Raised to $3
GuruFocus · 2026-09-29
B of A Securities Maintains Buy on 4D Molecular Therapeutics, Raises Price Target to $33
Benzinga · 2026-09-29
OCUL Stock Suffers Sharpest Drop Since February As KOD And FDMT Post Updates On Their Wet AMD Drugs
Yahoo · 2026-09-28
4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME
Yahoo · 2026-09-28
Scholastic Posts Downbeat Q1 Results, Joins Legacy Education, Zscaler And Other Big Stocks Moving Lower In Friday’s Pre-Market Session
Benzinga · 2026-09-25
4D Molecular Therapeutics (Nasdaq:FDMT) - Stock Analysis
Simply Wall Street · 2026-09-21
4D Molecular Therapeutics, Inc. (FDMT) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference Transcript
SeekingAlpha · 2026-09-17
4D Molecular Therapeutics (FDMT) CEO sells 58K shares under preset plan
Stock Titan · 2026-09-16
4D Molecular Therapeutics, Inc. (FDMT) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
SeekingAlpha · 2026-09-14
This Coinbase Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Monday
Benzinga · 2026-09-14
Cantor Fitzgerald Upgrades 4D Molecular Therapeutics to Overweight, Announces $20 Price Target
Benzinga · 2026-09-14

Informational purposes only, not investment advice.

4D Molecular Therapeutics, Inc. (FDMT)

tormere.com/research/FDMT · generated 2026-10-05

$13.67
-1.23%
General Information
Price$13.67
Change-1.23%
Market Cap$715M
SectorHealth Care
IndustryBiotechnology
ExchangeNasdaq
Beta (raw, 60mo vs SPY)2.71
Signals
Insider Velocity3896.3x selling
Congress Trades—
Short Volume
70% of daily vol
Conviction Score20/100
Analyst ConsensusSB 5 · B 10 · H 3 · S 0 · SS 0
Price Chart (1 Year)
2025-10-062026-10-02$16.76$7.19
Recent Insider Activity (Form 4) — Last 5
DateInsiderTypeSharesValue
2026-09-16Bizily ScottS1,635$22,317.75
2026-09-14Kirn DavidS58,333$811,003.7
2026-09-01Bizily ScottS584$8,176
2026-08-19Kirn DavidS25,927$425,651.34
2026-08-19Kirn DavidS43,149$662,621.93
Recent News
  • Insiders At 4D Molecular Therapeutics Sold US$757k In Stock, Alluding To Potential Weakness — Moomoo · 2026-09-30
  • 4D Molecular Therapeutics Insiders Sold US$757k Of Shares Suggesting Hesitancy — Simply Wall Street · 2026-09-30
  • This is the top biotech stock pick from B Riley Securities — Yahoo · 2026-09-29
  • 4D Molecular: Reiterate 'Buy' With Wet AMD 4D-150 Program On Track And Phase 3 DME Trial Underway — SeekingAlpha · 2026-09-29
  • FDMT Maintains by B of A Securities -- Price Target Raised to $3 — GuruFocus · 2026-09-29

Tormere — informational purposes only, not investment advice.

Factor Profile

Pro
Pro feature

Fama-French factor analysis is available on the Pro plan.

Upgrade to Pro →